{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:22:17Z","timestamp":1778656937134,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Academia Sinica, Taiwan","award":["IBMS-CRC101-P01"],"award-info":[{"award-number":["IBMS-CRC101-P01"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jneuroim.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T15:28:29Z","timestamp":1518103709000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets"],"prefix":"10.1016","volume":"318","author":[{"given":"Peng-Peng","family":"Ip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yen","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Fang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ie-Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy Shen-Jang","family":"Fann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2018.02.002_bb0005","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/1352458512473362","article-title":"CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions","volume":"19","author":"Alvarez","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2016.03.012","article-title":"Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFbeta in patients with Multiple Sclerosis","volume":"70","author":"Blumenfeld","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cca.2014.11.004","article-title":"Biomarkers for neuromyelitis optica","volume":"440","author":"Chang","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/978-1-4939-1154-7_24","article-title":"Galectins and neuroinflammation","volume":"9","author":"Chen","year":"2014","journal-title":"Adv. Neurobiol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083036","article-title":"Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica","volume":"8","author":"Chihara","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0165-5728(01)00261-2","article-title":"Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies","volume":"115","author":"Franciotta","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jaut.2011.08.003","article-title":"B cells undergo unique compartmentalized redistribution in multiple sclerosis","volume":"37","author":"Haas","year":"2011","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0040","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1474-4422(05)70179-4","article-title":"\u201cOSMS is NMO, but not MS\u201d: confirmed by NMO-IgG?","volume":"4","author":"Kikuchi","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0045","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(03)00308-9","article-title":"Multiple sclerosis in the Japanese population","volume":"2","author":"Kira","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0055","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1365-2249.2002.01947.x","article-title":"T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking","volume":"129","author":"Kivisakk","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cyto.2015.10.001","article-title":"CSF cytokines\/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review","volume":"77","author":"Kothur","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7224\/1537-2073-14.4.209","article-title":"Differentiation of neuromyelitis optica from multiple sclerosis on spinal magnetic resonance imaging","volume":"14","author":"Lalan","year":"2012","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0070","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.nurt.2010.05.014","article-title":"Microglial activation and chronic neurodegeneration","volume":"7","author":"Lull","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0080","first-page":"498","article-title":"Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis","volume":"72","author":"Mahad","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0085","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/brain\/awm027","article-title":"Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese","volume":"130","author":"Matsuoka","year":"2007","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0090","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/brain\/awf260","article-title":"Pure optic-spinal form of multiple sclerosis in Japan","volume":"125","author":"Misu","year":"2002","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0095","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1172\/JCI58649","article-title":"Multiple sclerosis","volume":"122","author":"Nylander","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jns.2015.05.034","article-title":"Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: a review","volume":"355","author":"Pereira","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0110","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1096\/fj.14-258194","article-title":"A role for the TIM-3\/GAL-9\/BAT3 pathway in determining the clinical phenotype of multiple sclerosis","volume":"28","author":"Saresella","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0115","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1468-1331.2001.00327.x","article-title":"Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis","volume":"8","author":"Sorensen","year":"2001","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0120","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2990.2011.01184.x","article-title":"Increased expression of distinct galectins in multiple sclerosis lesions","volume":"37","author":"Stancic","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12974-014-0144-0","article-title":"Astrocyte galectin-9 potentiates microglial TNF secretion","volume":"11","author":"Steelman","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-immunol-032713-120227","article-title":"Immunology of relapse and remission in multiple sclerosis","volume":"32","author":"Steinman","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0135","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2377-10-113","article-title":"Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"10","author":"Uzawa","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0165-5728(02)00352-1","article-title":"Chemokine receptors associated with immunity within and outside the central nervous system in early relapsing-remitting multiple sclerosis","volume":"133","author":"Wang","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0155","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1474-4422(06)70333-7","article-title":"OSMS is NMO, but not MS: proven clinically and pathologically","volume":"5","author":"Weinshenker","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0160","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0165","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2013.04.021","article-title":"IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis","volume":"261","author":"Xu","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0175","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2011.10.001","article-title":"Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica","volume":"240-241","author":"Zhong","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2018.02.002_bb0180","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817304988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817304988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:31:56Z","timestamp":1759048316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572817304988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":36,"alternative-id":["S0165572817304988"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.02.002","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}